Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Expanding the use of ctDNA in clinical trials

Stacey Cohen • 12 Sep 2022
ESMO 2022
General

Stacey Cohen, MD, University of Washington, Seatlle, WA, discusses the importance of expanding the use of circulating tumor DNA (ctDNA) in clinical trials. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Stacey Cohen

0:31
Highlights in colorectal cancer at ASCO GI 2023
Stacey Cohen • 20 Jan 2023
0:59
Practical considerations for genomic testing in colorectal cancer
Stacey Cohen • 20 Jan 2023
2:17
Does postoperative cfDNA affect MRD detection rates in CRC?
Stacey Cohen • 20 Jan 2023
0:31
Applications of ctDNA in the management of colorectal cancer
Stacey Cohen • 20 Jan 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals